Diversity in receptor signalling: cellular individuality and the search for selective drugs.
Recent developments in the molecular pharmacology of receptor signalling are reviewed. Receptors and other signalling molecules belong to superfamilies characterized by variations on given themes. A remarkable degree of diversity is generated by unique combinations of molecular entities, and there are also interactions between parallel signal transduction pathways. Molecular biology techniques have revealed new targets for drug development, as well as new methods of drug testing. However, it is not yet clear whether molecular and biochemical specificity always correspond to clinical selectivity.
Fredholm
B B
BB
Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden.
D000818:Animals; D019204:GTP-Binding Proteins / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D011955:Receptors, Drug / Q000737:chemistry / Q000502:physiology*; D011963:Receptors, GABA-A / Q000502:physiology; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000502:physiology; D015290:Second Messenger Systems / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
D011955:Receptors, Drug; D011963:Receptors, GABA-A; D011978:Receptors, Nicotinic; D019204:GTP-Binding Proteins